A carregar...
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
BACKGROUND: Data on efficacy of bevacizumab (B) beyond first-line taxane -including regimen (BT) as first-line treatment are lacking. Although preclinical results that anti-angiogenic agents combined with hormonal therapy (HT) could be active, no clinical data exist about combination of maintenance...
Na minha lista:
Main Authors: | , , , , , , , , , , |
---|---|
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
BioMed Central
2012
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3488474/ https://ncbi.nlm.nih.gov/pubmed/23083011 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-12-482 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|